Codexis, Inc.
CDXSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2026 | Stifel Nicolaus | Daniel Arias | $5.00(+194%) | $1.70 | StreetInsider |
| May 30, 2024 | Cantor Fitzgerald | Kristen Kluska | $11.00(+245%) | $3.19 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Piper Sandler | maintain | Overweight | Aug 17, 2026 |
| Cantor Fitzgerald | maintain | Overweight | Nov 22, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Nov 15, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Sep 20, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Aug 29, 2024 |
| Benchmark | downgrade | Buy →Hold | Aug 19, 2024 |
| Cantor Fitzgerald | maintain | Overweight | Aug 9, 2024 |
| Benchmark | maintain | Buy | May 3, 2024 |
| Benchmark | upgrade | Hold →Buy | Feb 29, 2024 |
| Benchmark | downgrade | Buy →Hold | Nov 7, 2023 |
| Piper Sandler | maintain | Overweight | Nov 6, 2023 |
| Benchmark | maintain | Buy | Sep 1, 2023 |
| Stifel | maintain | Buy | Aug 14, 2023 |
| Stephens & Co. | maintain | Overweight | Jul 21, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | May 9, 2023 |
| Benchmark | maintain | Buy | May 9, 2023 |
| Piper Sandler | maintain | Overweight | Apr 17, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 27, 2023 |
| Piper Sandler | maintain | Overweight | Jan 19, 2023 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2022 |
| HC Wainwright & Co. | maintain | Buy | Aug 8, 2022 |
| HC Wainwright & Co. | maintain | Buy | Jul 18, 2022 |
| Cowen & Co. | maintain | Outperform | Jul 15, 2022 |
| Piper Sandler | maintain | Overweight | Jul 15, 2022 |
| Stephens & Co. | maintain | Overweight | May 11, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.13 | $-0.14 | $14.9M | $13.8M |
| May 7, 2026 | $-0.10 | $-0.11 | $15.2M | $14.5M |
| Mar 11, 2026 | $0.11 | $0.01 | $38.9M | $35.8M |
| Nov 6, 2025 | $-0.22 | $-0.15 | $8.6M | $35.8M |
| Aug 13, 2025 | $-0.16 | $-0.17 | $15.3M | $19.5M |
| May 14, 2025 | $-0.25 | $-0.20 | $7.5M | $9.7M |
| Feb 27, 2025 | $-0.13 | $-0.04 | $21.5M | $27.4M |
| Oct 31, 2024 | $-0.29 | $-0.25 | $12.8M | $27.4M |
News
REDWOOD CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2026 on Thursday, November 12, 2026, following the close of market.
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform.
Revvity (NYSE: RVTY - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Institutional and Insider Ownership 86.7% of Revvity shares are held
Mettler-Toledo International (NYSE: MTD - Get Free Report) and Codexis (NASDAQ: CDXS - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, profitability and analyst recommendations. Volatility and Risk Mettler-Toledo International has a beta of
BlackRock Inc. bought a new stake in shares of Codexis, Inc. (NASDAQ: CDXS) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund bought 7,284,352 shares of the biotechnology company's stock, valued at approximately $16,463,000. BlackRock Inc. owned 8.01% of Codexis as of its most recent
REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York.
Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Codexis, Inc. (CDXS) Q2 2026 Earnings Call Transcript
Codexis (CDXS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.16 per share a year ago.
Codexis NASDAQ: CDXS reported second-quarter 2026 revenue of $14.9 million, compared with $15.3 million in the prior-year period, as the company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis® Manufacturing Platform exerts enzyme-driven stereoisomer control of siRNA Completed successful equity capital raise of approximately $25 million in net proceeds REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions f…